Form 4: Serina Therapeutics CSO Sells Shares

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, executed pre-planned sales of common stock totaling 4,000 shares over two days in January 2026.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. (SER), reported transactions involving the company's common stock.
• The reported transactions were made pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan for the purchase or sale of equity securities.
• On January 20, 2026, Mr. Moreadith exercised stock options to acquire 2,000 shares of common stock at an exercise price of $0.06 per share.
• Immediately following the option exercise on January 20, 2026, Mr. Moreadith sold these 2,000 shares of common stock at a price of $3.07 per share.
• On January 21, 2026, Mr. Moreadith again exercised stock options to acquire 2,000 shares of common stock at an exercise price of $0.06 per share.
• Immediately following the option exercise on January 21, 2026, Mr. Moreadith sold these 2,000 shares of common stock at a price of $3.00 per share.
• After these transactions, Mr. Moreadith beneficially owns 0 shares of common stock directly.
• Mr. Moreadith's beneficial ownership of stock options decreased from 330,686 to 328,686 after these exercises.

Sentiment

Score: 5

Explanation: The filing reports pre-planned insider transactions, which are neutral in terms of company operational performance or strategic direction. The transactions represent a routine exercise and sale of vested options.

Positives

• The exercise price of $0.06 for the stock options compared to the sale prices of $3.07 and $3.00 indicates a significant profit for the reporting person, reflecting the value of their compensation package.
• The transactions were conducted under a Rule 10b5-1(c) plan, indicating pre-planned sales and adherence to insider trading compliance protocols.

Negatives

• The sale of shares by a Chief Scientific Officer, even if pre-planned, could be interpreted by some investors as a signal, potentially impacting market sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions, particularly sales, are routinely monitored by investors as they can sometimes provide insights into management's perspective on the company's valuation or future prospects. However, transactions executed under a Rule 10b5-1 plan are pre-scheduled and generally considered less indicative of immediate sentiment.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe the insider sale and consider its implications, though the pre-planned nature under Rule 10b5-1 mitigates concerns about immediate insider sentiment.

Key Dates

Keywords

Serina Therapeutics, SER, Form 4, insider trading, stock options, share sale, Chief Scientific Officer, Randall Moreadith, Rule 10b5-1